Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry

Bente Glintborg, Mikkel Ostergaard, Niels Steen Krogh, Martin Dehn Andersen, Ulrik Tarp, Anne Gitte Loft, Hanne Lindegaard, Mette Holland-Fischer, Henrik Nordin, Dorte Vendelbo Jensen, Christian Holkmann Olsen, Merete Lund Hetland

175 Citationer (Scopus)

Abstract

To describe the frequency of treatment switching and outcomes among patients with psoriatic arthritis (PsA) who switched tumor necrosis factor α inhibitor (TNFi) agents in routine care.
OriginalsprogEngelsk
TidsskriftExcerpta Medica. Section 31: Arthritis and Rheumatism
Vol/bind65
Udgave nummer5
Sider (fra-til)1213-23
Antal sider11
ISSN0014-4355
DOI
StatusUdgivet - maj 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry'. Sammen danner de et unikt fingeraftryk.

Citationsformater